APO Research
Talk to an analyst

APO RESEARCH · REPORT

Platelet-Derived Growth Factor Receptor Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Platelet-Derived Growth Factor Receptor Inhibitors Market Analysis and Forecast 2026-2032

29 December 2025190 pages

Choose your research edition.

Industry ResearchPlatelet-Derived Growth Factor Receptor Inhibitors Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Platelet-Derived Growth Factor Receptor Inhibitors Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Platelet-Derived Growth Factor Receptor Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platelet-Derived Growth Factor Receptor Inhibitors Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Platelet-Derived Growth Factor Receptor Inhibitors Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Platelet-Derived Growth Factor Receptor Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Platelet-Derived Growth Factor Receptor Inhibitors include Il-Yang Pharmaceutical, Takeda, Eisai, Novartis, Eli Lilly, Pfizer, GSK, Boehringer Ingelheim and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Platelet-Derived Growth Factor Receptor Inhibitors, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Platelet-Derived Growth Factor Receptor Inhibitors, also provides the revenue of main regions and countries. Of the upcoming market potential for Platelet-Derived Growth Factor Receptor Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Platelet-Derived Growth Factor Receptor Inhibitors revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Platelet-Derived Growth Factor Receptor Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Platelet-Derived Growth Factor Receptor Inhibitors revenue, projected growth trends, production technology, application and end-user industry.

Platelet-Derived Growth Factor Receptor Inhibitors Segment by Company

Il-Yang Pharmaceutical

Takeda

Eisai

Novartis

Eli Lilly

Pfizer

GSK

Boehringer Ingelheim

Bayer

Bristol-Myers Squibb

Platelet-Derived Growth Factor Receptor Inhibitors Segment by Type

Capsules

Tablets

Others

Platelet-Derived Growth Factor Receptor Inhibitors Segment by Application

Hospitals

Clinics

Platelet-Derived Growth Factor Receptor Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platelet-Derived Growth Factor Receptor Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platelet-Derived Growth Factor Receptor Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platelet-Derived Growth Factor Receptor Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Platelet-Derived Growth Factor Receptor Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Platelet-Derived Growth Factor Receptor Inhibitors company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Platelet-Derived Growth Factor Receptor Inhibitors revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Capsules Major Player Table 3. Tablets Major Player Table 4. Others Major Player Table 5. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Platelet-Derived Growth Factor Receptor Inhibitors Industry Trends Table 9. Platelet-Derived Growth Factor Receptor Inhibitors Industry Drivers Table 10. Platelet-Derived Growth Factor Receptor Inhibitors Industry Opportunities and Challenges Table 11. Platelet-Derived Growth Factor Receptor Inhibitors Industry Restraints Table 12. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Share by Region (2021-2026) Table 15. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Share by Region (2027-2032) Table 17. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Players (2021-2026) Table 19. Global Platelet-Derived Growth Factor Receptor Inhibitors Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Platelet-Derived Growth Factor Receptor Inhibitors Key Players Headquarters & Area Served Table 21. Global Platelet-Derived Growth Factor Receptor Inhibitors Players, Product Type & Application Table 22. Global Platelet-Derived Growth Factor Receptor Inhibitors Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Platelet-Derived Growth Factor Receptor Inhibitors by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Application (2021-2026) Table 34. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Application (2027-2032) Table 35. Il-Yang Pharmaceutical Company Information Table 36. Il-Yang Pharmaceutical Business Overview Table 37. Il-Yang Pharmaceutical Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Il-Yang Pharmaceutical Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 39. Il-Yang Pharmaceutical Recent Development Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 44. Takeda Recent Development Table 45. Eisai Company Information Table 46. Eisai Business Overview Table 47. Eisai Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Eisai Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 49. Eisai Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novartis Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 54. Novartis Recent Development Table 55. Eli Lilly Company Information Table 56. Eli Lilly Business Overview Table 57. Eli Lilly Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Eli Lilly Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 59. Eli Lilly Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Pfizer Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 64. Pfizer Recent Development Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GSK Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 69. GSK Recent Development Table 70. Boehringer Ingelheim Company Information Table 71. Boehringer Ingelheim Business Overview Table 72. Boehringer Ingelheim Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Boehringer Ingelheim Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 74. Boehringer Ingelheim Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bayer Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 79. Bayer Recent Development Table 80. Bristol-Myers Squibb Company Information Table 81. Bristol-Myers Squibb Business Overview Table 82. Bristol-Myers Squibb Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Bristol-Myers Squibb Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio Table 84. Bristol-Myers Squibb Recent Development Table 85. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 99. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 100. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 101. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 102. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Platelet-Derived Growth Factor Receptor Inhibitors Image Figure 2. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Capsules Image Figure 5. Tablets Image Figure 6. Others Image Figure 7. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size (US$ Million) & (2021-2032) Figure 12. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Platelet-Derived Growth Factor Receptor Inhibitors Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Platelet-Derived Growth Factor Receptor Inhibitors Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Type (2021-2032) Figure 19. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Application (2021-2032) Figure 22. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032) Figure 24. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032) Figure 25. North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Country (2021-2032) Figure 26. United States Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032) Figure 31. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032) Figure 32. Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Country (2021-2032) Figure 33. Germany Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032) Figure 43. China Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032) Figure 44. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032) Figure 46. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032) Figure 47. Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Region (2021-2032) Figure 48. Japan Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032) Figure 56. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032) Figure 57. SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Country (2021-2032) Figure 58. Brazil Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Platelet-Derived Growth Factor Receptor Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Tablets
  • Others
Applications
  • Hospitals
  • Clinics
Companies covered
  • Il-Yang Pharmaceutical
  • Takeda
  • Eisai
  • Novartis
  • Eli Lilly
  • Pfizer
  • GSK
  • Boehringer Ingelheim
  • Bayer
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Platelet-Derived Growth Factor Receptor Inhibitors Market by Type
  3. 1.2.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Capsules
  5. 1.2.3 Tablets
  6. 1.2.4 Others
  7. 1.3 Platelet-Derived Growth Factor Receptor Inhibitors Market by Application
  8. 1.3.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Platelet-Derived Growth Factor Receptor Inhibitors Market Dynamics
  1. 2.1 Platelet-Derived Growth Factor Receptor Inhibitors Industry Trends
  2. 2.2 Platelet-Derived Growth Factor Receptor Inhibitors Industry Drivers
  3. 2.3 Platelet-Derived Growth Factor Receptor Inhibitors Industry Opportunities and Challenges
  4. 2.4 Platelet-Derived Growth Factor Receptor Inhibitors Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Perspective (2021-2032)
  2. 3.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Growth Trends by Region
  3. 3.2.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region (2021-2026)
  5. 3.2.3 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Players
  2. 4.1.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Players (2021-2026)
  3. 4.1.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Platelet-Derived Growth Factor Receptor Inhibitors Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Platelet-Derived Growth Factor Receptor Inhibitors Key Players Headquarters & Area Served
  7. 4.4 Global Platelet-Derived Growth Factor Receptor Inhibitors Players, Product Type & Application
  8. 4.5 Global Platelet-Derived Growth Factor Receptor Inhibitors Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Market CR5 and HHI
  11. 4.6.3 2025 Platelet-Derived Growth Factor Receptor Inhibitors Tier 1, Tier 2, and Tier 3
5 Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type
  1. 5.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2032)
  3. 5.3 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Type (2021-2032)
6 Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application
  1. 6.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2032)
  3. 6.3 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Il-Yang Pharmaceutical
  2. 7.1.1 Il-Yang Pharmaceutical Company Information
  3. 7.1.2 Il-Yang Pharmaceutical Business Overview
  4. 7.1.3 Il-Yang Pharmaceutical Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Il-Yang Pharmaceutical Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  6. 7.1.5 Il-Yang Pharmaceutical Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Eisai
  14. 7.3.1 Eisai Company Information
  15. 7.3.2 Eisai Business Overview
  16. 7.3.3 Eisai Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eisai Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  18. 7.3.5 Eisai Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 GSK
  38. 7.7.1 GSK Company Information
  39. 7.7.2 GSK Business Overview
  40. 7.7.3 GSK Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GSK Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  42. 7.7.5 GSK Recent Developments
  43. 7.8 Boehringer Ingelheim
  44. 7.8.1 Boehringer Ingelheim Company Information
  45. 7.8.2 Boehringer Ingelheim Business Overview
  46. 7.8.3 Boehringer Ingelheim Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Boehringer Ingelheim Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  48. 7.8.5 Boehringer Ingelheim Recent Developments
  49. 7.9 Bayer
  50. 7.9.1 Bayer Company Information
  51. 7.9.2 Bayer Business Overview
  52. 7.9.3 Bayer Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bayer Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  54. 7.9.5 Bayer Recent Developments
  55. 7.10 Bristol-Myers Squibb
  56. 7.10.1 Bristol-Myers Squibb Company Information
  57. 7.10.2 Bristol-Myers Squibb Business Overview
  58. 7.10.3 Bristol-Myers Squibb Platelet-Derived Growth Factor Receptor Inhibitors Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Myers Squibb Platelet-Derived Growth Factor Receptor Inhibitors Product Portfolio
  60. 7.10.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue (2021-2032)
  2. 8.2 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2032)
  3. 8.2.1 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026)
  4. 8.2.2 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032)
  5. 8.3 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032)
  6. 8.4 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2032)
  7. 8.4.1 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026)
  8. 8.4.2 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032)
  9. 8.5 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032)
  10. 8.6 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country
  11. 8.6.1 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026)
  13. 8.6.3 North America Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue (2021-2032)
  2. 9.2 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2032)
  3. 9.2.1 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026)
  4. 9.2.2 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032)
  5. 9.3 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032)
  6. 9.4 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2032)
  7. 9.4.1 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026)
  8. 9.4.2 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032)
  9. 9.5 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032)
  10. 9.6 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country
  11. 9.6.1 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026)
  13. 9.6.3 Europe Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue (2021-2032)
  2. 10.2 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2032)
  3. 10.2.1 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026)
  4. 10.2.2 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032)
  5. 10.3 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032)
  6. 10.4 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2032)
  7. 10.4.1 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026)
  8. 10.4.2 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032)
  9. 10.5 China Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue (2021-2032)
  2. 11.2 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2032)
  3. 11.2.1 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026)
  4. 11.2.2 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032)
  5. 11.3 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032)
  6. 11.4 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2032)
  7. 11.4.1 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026)
  8. 11.4.2 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032)
  9. 11.5 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032)
  10. 11.6 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country
  11. 11.6.1 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026)
  13. 11.6.3 Asia Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue (2021-2032)
  2. 12.2 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Type (2027-2032)
  5. 12.3 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Application (2027-2032)
  9. 12.5 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country
  11. 12.6.1 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst